VA and HHS Collaborate to Expand Psychedelic Therapy Research for PTSD Treatment

The Departments of Veterans Affairs (VA) and Health and Human Services (HHS) have signed an agreement aimed at enhancing research into psychedelic drugs as potential treatments for post-traumatic stress disorder (PTSD) and other mental health issues among veterans. The memorandum of understanding (MOU), announced on Monday, outlines plans to increase clinical trial participation, train medical professionals in the administration of psychedelic medications if they receive federal approval, and gather data to support patient care and regulatory considerations.

This initiative follows an executive order signed by President Donald Trump in April 2026, which directed the Food and Drug Administration (FDA) to accelerate its review process for several psychedelic treatments targeting mental illnesses. The order specifically addresses research on ibogaine, a hallucinogen derived from an African shrub that some veterans have found beneficial in managing symptoms of anxiety, PTSD, and depression.

Studies indicate that approximately one-third of individuals with PTSD may be resistant to conventional treatments, with up to 50% not responding adequately to psychological therapy and 40% remaining untreated by common medications. The VA is collaborating closely with the FDA to support the development of new therapies for serious mental health conditions, marking a significant step in addressing the unique challenges faced by veterans.

The agreement also highlights ongoing research efforts within the Department of Defense (DoD), including a $4.9 million study at Walter Reed National Military Medical Center focused on assessing MDMA's effectiveness in treating mild to moderate PTSD among active-duty troops. This project underscores the growing recognition of psychedelic substances as potential therapeutic agents for mental health disorders.

Ron Adkins, an Army Reserve intelligence analyst and veterans advocate who has deployed twice to Afghanistan, emphasized the importance of exploring innovative treatment options for complex mental illnesses. "The cognitive space is a very intricate environment," Adkins noted. "Each individual's needs are unique, so treatments that work well for one person might not be effective for another."

Veterans have historically sought psychedelic therapies abroad, often at considerable personal expense and risk. The new agreement aims to address this by fostering domestic research and development of these treatments under regulated conditions. VA researchers are currently involved in over 20 trials investigating the use of psychedelics like MDMA and psilocybin for treating severe PTSD, depression, substance abuse, and other mental health issues.

Despite initial regulatory hurdles, such as the FDA's rejection of a request to approve MDMA for PTSD treatment in adults due to insufficient evidence regarding safety and efficacy, VA officials remain committed to advancing this field. A study underway in Providence, Rhode Island, involves 80 veterans comparing MDMA-assisted therapy with placebo treatments to determine its effectiveness.

Healthcare providers at VA facilities advise against self-medicating or substituting prescribed therapies with unauthorized substances. "Proven, evidence-based treatments are currently available at VA facilities," officials stated. "Veterans should always consult their healthcare providers before making any treatment decisions."

The collaboration between the VA and HHS marks a pivotal moment in the exploration of psychedelic therapy for veterans' mental health conditions, promising new avenues for addressing long-standing challenges in PTSD treatment.